drs. fizazi, wallis on updated data from talapro-2
Published 1 year ago • 291 plays • Length 11:19Download video MP4
Download video MP3
Similar videos
-
10:07
the oncology brothers, dr. wallis give their thoughts on propel, talapro-2, and ev-103 cohort k
-
3:56
the landscape of utuc treatment integration: drs. coleman and wallis
-
6:35
talazoparib plus enzalutamide: talapro-2 results and subset analyses
-
6:54
talapro-2: toxicities and treatment duration
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
7:52
does high psa levels = prostate cancer? | dr steven tucker
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
12:08
new fda approval: darolutamide for hormone-sensitive disease | mark scholz, md | pcri
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
1:38
novel combination therapy regimen shows promising results for prostate cancer
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
8:09
comparing apalutamide and enzalutamide in real-world treatment of mcspc
-
5:52
talapro-1: phase ii study of talazoparib in patients with dna damage repair alterations and mcrpc
-
38:32
optimal treatment sequence for patients with castration resistant prostate cancer - karim fizazi
-
2:10
strong: fixed-dose durvalumab for utc
-
0:56
dr. trabulsi defines locally advanced prostate cancer
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
5:36
propel trial
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
2:37
latitude: combination therapy for newly diagnosed prostate cancer
-
1:05
dr. peeters on the utility of aflibercept in advanced colorectal cancer